Key Takeaways
- Johnson & Johnson delivered Q1 adjusted earnings of $2.70 per share, surpassing the analyst consensus of $2.68, while revenue reached $24.1 billion versus expectations of $23.6 billion.
- The pharmaceutical segment grew 11.2% compared to last year, generating $15.4 billion, with Darzalex contributing $4.0B and Tremfya adding $1.6B.
- Full-year 2026 revenue projections were increased to $100.8 billion, while adjusted earnings per share guidance rose to $11.55.
- The newly approved psoriasis medication Icotyde has potential to generate approximately $10 billion in peak annual sales, according to Truist Securities analysts.
- Year-to-date performance shows JNJ stock climbing 15% in 2026, significantly outpacing the S&P 500’s modest 0.6-1% increase.
Johnson & Johnson unveiled its first-quarter 2026 financial performance on Tuesday morning, delivering figures that exceeded Wall Street projections across key metrics.
Revenue for the quarter reached $24.1 billion, representing a 10% increase compared to the prior-year period and topping the analyst forecast of $23.6 billion compiled by FactSet. The company’s adjusted earnings per share came to $2.70, narrowly surpassing the consensus estimate of $2.68.
Shares of the healthcare giant rose approximately 1.2% during premarket trading hours following the earnings announcement.
This quarter represents the latest chapter in J&J’s strategic transformation. Over recent years, the corporation has deliberately shifted away from consumer health offerings — divesting the Kenvue business, which Kimberly-Clark is now in the process of acquiring — to focus exclusively on pharmaceuticals and medical technology.
The pharmaceutical division stood out as the performance leader, recording an 11.2% year-over-year increase to $15.4 billion. This figure exceeded the FactSet projection of $15.2 billion.
Darzalex, the company’s leading multiple myeloma treatment, generated $4.0 billion during the quarter, compared to $3.2 billion in the same period last year. Analysts had anticipated $3.9 billion.
Tremfya, an IL-23 inhibitor designed for autoimmune disorders, delivered $1.6 billion in quarterly sales, marking a substantial jump from $956 million a year earlier and comfortably beating the $1.4 billion forecast.
Autoimmune Innovation Takes Center Stage
Regulatory authorities granted approval for Tremfya’s subcutaneous formulation last September for individuals with ulcerative colitis and Crohn’s disease, establishing it as the first medication in its class that patients can administer themselves at home. This feature provides a competitive edge against AbbVie’s Skyrizi, which necessitates clinic-based infusions during the initial treatment phase.
In March, J&J secured FDA clearance for Icotyde, an innovative oral IL-23 inhibitor tablet for plaque psoriasis, stemming from a 2017 licensing agreement with Protagonist Therapeutics. Truist Securities analyst Srikripa Devarakonda projects Icotyde could achieve peak annual revenues approaching $10 billion. The company has not yet released any sales data for this product.
The medical devices segment recorded $8.6 billion in revenue, matching analyst projections.
Net profit totaled $5.2 billion, falling short of the FactSet estimate of $6.5 billion — marking the second straight quarter where bottom-line results disappointed expectations.
Updated Outlook and Ongoing Litigation
Looking ahead to the full year, J&J raised its revenue forecast to $100.8 billion from a previous projection of $100.5 billion. The company also elevated its adjusted EPS guidance to $11.55 from $11.03. Wall Street analysts had been anticipating $11.54 per share and $100.6 billion in revenue.
The corporation continues to navigate significant legal challenges. As of the fourth quarter of 2025, J&J was confronting 74,360 lawsuits related to allegations that it knowingly marketed talcum powder products contaminated with carcinogenic asbestos. The company’s latest effort to settle these claims through a bankruptcy filing via subsidiary Red River Talc was rejected by a Texas court, permitting individual legal actions to move forward.
J&J has consistently defended its baby powder product, now distributed under the Kenvue brand name, asserting it is safe and free from asbestos contamination.
Among 29 analyst firms monitored by FactSet, 17 assign JNJ a Buy rating or equivalent. Two firms rate it as a Sell.
JNJ stock has appreciated 15% year-to-date in 2026, dramatically outperforming the S&P 500’s approximately 0.6% to 1% gain during the identical timeframe.
